Organon & Co | OGN - Pasivo Circulante





Pasivo Circulante Cambio Fecha
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Celltrion KRW 292.71B 9.09B 2026-03
Cspc Pharmaceutical CNY 10.18B 65.36M 2025-12
Deva Holding AS TRY 6.43B 1.18B 2023-09
Dianthus Therapeutics USD 34.39M 3.89M 2026-06
Divis Laboratories Ltd INR 20.43B 3.15B 2026-03
Gilead Sciences USD 11.02B 1.54B 2026-06
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Kangmei Pharma CNY 5.38B 433.79M 2026-03
Knight Therapeutics CAD 165.26M 12.58M 2025-12
Laboratorios Farma EUR 199.84M 121.75M 2023-12
Malin Corporation EUR 1000K 500K 2024-12
Medical Developments International AUD 5.56M 2.26M 2025-12
Merck USD 27.73B 786M 2026-06
Neuren Pharmaceuticals AUD 4.34M 3.58M 2025-12
Novartis USD 31.37B 4.1B 2026-03
Organigram Holdings CAD 88.74M 5.31M 2026-03
Organon & Co USD 2.62B 116M 2026-06
Ovoca Bio EUR 1.3M 1.11M 2025-12
Pharma Mar EUR 98.42M 9.2M 2026-06
Qiagen NV USD 581.45M 102.34M 2026-06
Sartorius EUR 1.44B 668.7M 2026-06
Sino Biopharmaceutical CNY 24.85B 5.29B 2025-06
Tilray USD 259.32M 8.32M 2025-09
Zealand Pharma A/S 404M 260.96M 2026-03